BioCryst Pharma (BCRX) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq rallies as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.52 +3.40%
EPS Growth %: -43.8%
Financial Fact:
Loss on foreign currency derivative: -931K
Today's EPS Names:
INM, TRI, CRVL, More
EPS Growth %: -43.8%
Financial Fact:
Loss on foreign currency derivative: -931K
Today's EPS Names:
INM, TRI, CRVL, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q1 EPS of ($0.28), $0.02 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $68.4 million versus the consensus estimate of $71.47 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Citi expects ’continued memory undersupply’ in 2027
- Apple shares slip amid guidance for tightening margins, slowing services growth
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
